Update of fecal markers of inflammation in inflammatory bowel disease

Thomas A. Judd; Andrew S. Day; Daniel A. Lemberg; Dan Turner; Steven T. Leach

doi:10.1111/j.1440-1746.2011.06846.x

Update of fecal markers of inflammation in inflammatory bowel disease

Thomas A. Judd, Andrew S. Day, Daniel A. Lemberg, Dan Turner, Steven T. Leach^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

76 Scopus citations

Abstract

The diagnosis, prognosis, and assessment of disease activity of inflammatory bowel disease (IBD) require investigating clinical, radiological, and histological criteria, as well as serum inflammatory markers. However, a range of fecal inflammatory markers now appears to have the potential to greatly assist in these processes. Calprotectin, a prominent neutrophil protein, was identified two decades ago as a potentially revolutionary marker for IBD. Following this discovery, numerous additional markers, including S100A12, lactoferrin, and M2-pyruvate kinase, have also been suggested as novel markers of IBD. In the present study, we provide an up-to-date review of fecal markers of IBD, and further, provide a novel analysis of each of these fecal markers in severe ulcerative colitis and compare their expression pattern in contrast to calprotectin.

Original language	English
Pages (from-to)	1493-1499
Number of pages	7
Journal	Journal of Gastroenterology and Hepatology (Australia)
Volume	26
Issue number	10
DOIs	https://doi.org/10.1111/j.1440-1746.2011.06846.x
State	Published - Oct 2011
Externally published	Yes

Keywords

Calprotectin
Fecal marker
Inflammatory bowel disease
Lactoferrin
M2-pyruvate kinase
S100A12

Access to Document

10.1111/j.1440-1746.2011.06846.x

Cite this

@article{3fa4aefc9bec4c6a9d02c37d8954becb,

title = "Update of fecal markers of inflammation in inflammatory bowel disease",

abstract = "The diagnosis, prognosis, and assessment of disease activity of inflammatory bowel disease (IBD) require investigating clinical, radiological, and histological criteria, as well as serum inflammatory markers. However, a range of fecal inflammatory markers now appears to have the potential to greatly assist in these processes. Calprotectin, a prominent neutrophil protein, was identified two decades ago as a potentially revolutionary marker for IBD. Following this discovery, numerous additional markers, including S100A12, lactoferrin, and M2-pyruvate kinase, have also been suggested as novel markers of IBD. In the present study, we provide an up-to-date review of fecal markers of IBD, and further, provide a novel analysis of each of these fecal markers in severe ulcerative colitis and compare their expression pattern in contrast to calprotectin.",

keywords = "Calprotectin, Fecal marker, Inflammatory bowel disease, Lactoferrin, M2-pyruvate kinase, S100A12",

author = "Judd, {Thomas A.} and Day, {Andrew S.} and Lemberg, {Daniel A.} and Dan Turner and Leach, {Steven T.}",

year = "2011",

month = oct,

doi = "10.1111/j.1440-1746.2011.06846.x",

language = "אנגלית",

volume = "26",

pages = "1493--1499",

journal = "Journal of Gastroenterology and Hepatology (Australia)",

issn = "0815-9319",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "10",

}

TY - JOUR

T1 - Update of fecal markers of inflammation in inflammatory bowel disease

AU - Judd, Thomas A.

AU - Day, Andrew S.

AU - Lemberg, Daniel A.

AU - Turner, Dan

AU - Leach, Steven T.

PY - 2011/10

Y1 - 2011/10

N2 - The diagnosis, prognosis, and assessment of disease activity of inflammatory bowel disease (IBD) require investigating clinical, radiological, and histological criteria, as well as serum inflammatory markers. However, a range of fecal inflammatory markers now appears to have the potential to greatly assist in these processes. Calprotectin, a prominent neutrophil protein, was identified two decades ago as a potentially revolutionary marker for IBD. Following this discovery, numerous additional markers, including S100A12, lactoferrin, and M2-pyruvate kinase, have also been suggested as novel markers of IBD. In the present study, we provide an up-to-date review of fecal markers of IBD, and further, provide a novel analysis of each of these fecal markers in severe ulcerative colitis and compare their expression pattern in contrast to calprotectin.

AB - The diagnosis, prognosis, and assessment of disease activity of inflammatory bowel disease (IBD) require investigating clinical, radiological, and histological criteria, as well as serum inflammatory markers. However, a range of fecal inflammatory markers now appears to have the potential to greatly assist in these processes. Calprotectin, a prominent neutrophil protein, was identified two decades ago as a potentially revolutionary marker for IBD. Following this discovery, numerous additional markers, including S100A12, lactoferrin, and M2-pyruvate kinase, have also been suggested as novel markers of IBD. In the present study, we provide an up-to-date review of fecal markers of IBD, and further, provide a novel analysis of each of these fecal markers in severe ulcerative colitis and compare their expression pattern in contrast to calprotectin.

KW - Calprotectin

KW - Fecal marker

KW - Inflammatory bowel disease

KW - Lactoferrin

KW - M2-pyruvate kinase

KW - S100A12

UR - http://www.scopus.com/inward/record.url?scp=80053101697&partnerID=8YFLogxK

U2 - 10.1111/j.1440-1746.2011.06846.x

DO - 10.1111/j.1440-1746.2011.06846.x

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???

AN - SCOPUS:80053101697

SN - 0815-9319

VL - 26

SP - 1493

EP - 1499

JO - Journal of Gastroenterology and Hepatology (Australia)

JF - Journal of Gastroenterology and Hepatology (Australia)

IS - 10

ER -

Update of fecal markers of inflammation in inflammatory bowel disease

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this